Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Subcutaneous MD-18 in Healthy Subjects
NCT06259903Phase 1Active, not recruiting
- Sponsor
- Cohen Global
- Start
- May 2024
- Primary completion
- Dec 2024
- Modality
- Small Molecules, Modified Peptides, Native Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of MD-18 in obesity (5 arms), sponsored by Cohen Global. Primary endpoints: Adverse Events at 2 months, Pharmacokinetics samples at Day 1 and 5 more. Started May 2024; status: active, not recruiting.
02
Drugs
MD-18
03
Conditions
obesity
Beyond the preview
Go deeper on NCT06259903.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06259903.